Sarepta Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Sarepta Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sarepta Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sarepta Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sarepta Therapeutics Inc (Sarepta) discovers and develops RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic Medicine in gene therapy, RNA, and gene editing. The company’s platform is based on its pioneering work with phosphorodiamidate morpholino oligomer (PMO) chemistries. Its commercial products include Exondys 51, Vyondys 53, Elevidys and Amondys 45 indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene. Its pipeline product includes SRP-6004, SRP-9003 and SRP-9004 indicated for the treatment of DMD, limb-girdle muscular dystrophies (LGDMs) and other neuromuscular and central nervous system disorders. Geographically, the company has presence in the US, the UK, Switzerland and Ireland. Sarepta is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
215 First Street, Cambridge, Massachusetts, 02142
Website
www.sarepta.com
Telephone
1 617 2744000
No of Employees
835
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SRPT (NASD)
Revenue (2024)
$2.2B
15.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-403.3%
(2024 vs 2023)
Market Cap*
$2.2B
Net Profit Margin (2024)
XYZ
-362.3%
(2024 vs 2023)
* As of and is in US$
Sarepta Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Amondys 45 - Duchenne Muscular Dystrophy | - |
| Vyondys 53 - Duchenne Muscular Dystrophy | VYONDYS |
| Exondys 51 - Duchenne Muscular Dystrophy | EXONDYS |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In February, the company launched ELEVIDYS (delandistrogene moxeparvovec) in Japan. |
| 2026 | Others | In January, the company submitted its clinical trial application for Study SRP-1005-101 to Medsafe for the treatment of Huntington’s Disease. |
| 2025 | Regulatory Approval | In November, the company secured approval from the U.S. Food and Drug Administration for dosing in Cohort 8 of ENDEAVOR. |
Competitor Comparison
| Key Parameters | Sarepta Therapeutics Inc | Eli Lilly and Co | Sanofi | Biogen Inc | Alnylam Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | United States of America | United States of America |
| City | Cambridge | Indianapolis | Paris | Cambridge | Cambridge |
| State/Province | Massachusetts | Indiana | Ile-de-France | Massachusetts | Massachusetts |
| No. of Employees | 835 | 50,605 | 76,493 | 7,500 | 2,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Douglas S. Ingram | Chief Executive Officer; Director; President | Executive Board | 2017 | 63 |
| M. Kathleen Behrens, Ph.D. | Chairwoman | Executive Board | 2015 | 73 |
| Ryan H.Wong | Chief Financial Officer; Executive Vice President | Senior Management | 2025 | 47 |
| Ian M. Estepan | Chief Operating Officer; President | Senior Management | 2025 | 50 |
| Alison Nasisi | Chief People Officer; Executive Vice President | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer